Abstract P1175: Endometriosis diagnosis, staging, and typology in relation to dyslipidemia

K Karen Schliep (UNIVERSITY UTAH, Salt Lake City, Utah, United States) A Anna Pollack (George Mason University, Fairfax, Virginia, United States) K Kathryn Rexrode (BRIGHAM AND WOMENS HOSPITAL, Boston, Massachusetts, United States) R Rachael Hemmert (University of Utah Health, Salt Lake City, Utah, United States) M Madeline Paulsen (University of Utah Health, Salt Lake City, Utah, United States) J Jessica Chan (UNIVERSITY UTAH, Salt Lake City, Utah, United States) H Hediyeh Baradaran J Jennifer Majersik (UNIVERSITY UTAH, Salt Lake City, Utah, United States) M Michael Varner (UNIVERSITY UTAH, Salt Lake City, Utah, United States) M Matt Peterson (UNIVERSITY UTAH, Salt Lake City, Utah, United States) J Joseph Stanford (UNIVERSITY UTAH, Salt Lake City, Utah, United States) J Jenna Krall (George Mason University, Fairfax, Virginia, United States) J Jessica Page (Intermountain Health, Salt Lake City, Utah, United States) L Leslie Farland (University of Arizona, Tucson, Arizona, United States)

Abstract

Background: Individuals with endometriosis, a gynecologic condition affecting approximately 11% of people with a uterus, may have an elevated risk for developing cardiovascular disease (CVD) later in life. However, the mechanisms underlying this association are not well understood. Methods: We investigated the association between incident endometriosis diagnosis, staging, and typology and lipid biomarkers measured at time of diagnostic surgery among women participating in the NICHD ENDO study (n=395). Endometriosis was categorized using the American Society for Reproductive Medicine staging (I−IV). Endometriosis typology was defined by lesion depth and location and categorized as superficial endometriosis (SE), ovarian endometrioma (OE), and deep infiltrating endometriosis (DE). With no endometriosis as our reference, we evaluated the associations between endometriosis diagnosis, stage (I/II vs III/IV), and typology (SE, OE, DE, OE+DE) and dyslipidemia using standard clinical thresholds (total cholesterol ≥200 mg/dL, high-density lipoprotein (HDL) <50 mg/dL, low-density lipoprotein (LDL) ≥100 mg/dL, triglycerides ≥175 mg/dL, non-HDL ≥130 mg/dL, VLDL ≥30 mg/dL, Apolipoprotein A-1 (APO-A1) <125 mg/dL, Apolipoprotein B (APOB) ≥120 mg/dL; APOB/APO-A1 ratio >0.78). We calculated adjusted prevalence ratios (aPR) and 95% CIs via generalized linear models, controlling for age, race/ethnicity, marital status, BMI, income (poverty level), and serum cotinine as a marker of smoking. Results: At the time of gynecologic surgery, individuals were mean 32 years (SD: 7 years), non-Hispanic white (79%), married (71%), and mean BMI 28 (SD=8). While we found no differences in endometriosis diagnosis or endometriosis staging and dyslipidemia ( Figure 1; Table 1 ), a pattern emerged regarding endometriosis typology ( Table 2 ). Women with OE+DE, compared to no endometriosis, had increased prevalence of dyslipidemia: total cholesterol >200 mg/dL: 1.87 (0.99, 3.57); triglycerides > 175 mg/dL: 2.48 (1.34, 4.57); VLDL ≥30 mg/dL: 2.08 (1.28, 3.38); and APOB mg/dL ≥120: 2.86 (1.22, 6.66). OE appeared to be driving this association. SE was not associated with dyslipidemia. Conclusions: The association between endometriosis, especially of more severe typology, and subsequent CVD may be through dyslipidemia, which may be detectable at the time of endometriosis diagnosis. Further research in larger, more representative samples is needed before definitive conclusions can be made.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (14)

K

Karen Schliep

UNIVERSITY UTAH, Salt Lake City, Utah, United States

A

Anna Pollack

George Mason University, Fairfax, Virginia, United States

K

Kathryn Rexrode

BRIGHAM AND WOMENS HOSPITAL, Boston, Massachusetts, United States

R

Rachael Hemmert

University of Utah Health, Salt Lake City, Utah, United States

M

Madeline Paulsen

University of Utah Health, Salt Lake City, Utah, United States

J

Jessica Chan

UNIVERSITY UTAH, Salt Lake City, Utah, United States

H

Hediyeh Baradaran

J

Jennifer Majersik

UNIVERSITY UTAH, Salt Lake City, Utah, United States

M

Michael Varner

UNIVERSITY UTAH, Salt Lake City, Utah, United States

M

Matt Peterson

UNIVERSITY UTAH, Salt Lake City, Utah, United States

J

Joseph Stanford

UNIVERSITY UTAH, Salt Lake City, Utah, United States

J

Jenna Krall

George Mason University, Fairfax, Virginia, United States

J

Jessica Page

Intermountain Health, Salt Lake City, Utah, United States

L

Leslie Farland

University of Arizona, Tucson, Arizona, United States